Grants per year
- 1 - 25 out of 40 results
Search results
-
Active
Prot #BGB-11417-203: An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination with Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia
Ma, S. (PD/PI)
9/27/24 → 9/27/27
Project: Research project
-
Prot #M23-647: First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants with B-cell Malignancies
Ma, S. (PD/PI)
5/28/24 → 5/28/27
Project: Research project
-
Prot #NU MSK20H06: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study of Ibrutinib in Combination With Rituximab in Subjects With Treatment Naïve Marginal Zone Lymphoma
Ma, S. (PD/PI)
Memorial Sloan Kettering Cancer Center, Pharmacyclics, Inc.
10/12/22 → 10/12/25
Project: Research project
-
Prot #BGB-11417-101: A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies
Ma, S. (PD/PI)
8/5/21 → 8/5/27
Project: Research project
-
Prot #ACE-LY-003: An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma
Ma, S. (PD/PI)
Syneos Health, Inc., Acerta Pharma, LLC
8/21/19 → 12/31/26
Project: Research project
-
Prot #BGB-3111-304: An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ma, S. (PD/PI)
PRA Health Sciences, BeiGene Ltd.
2/5/19 → 2/5/27
Project: Research project
-
Prot #ACE-CL-208: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Ma, S. (PD/PI)
INC Research, LLC, Acerta Pharma B.V.
5/15/16 → 5/15/25
Project: Research project
-
Prot #PCI-32765CAN3001: A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study
Ma, S. (PD/PI)
Janssen Research & Development, LLC
5/27/15 → 5/20/26
Project: Research project
-
Prot #X12-11008: NU 13H05: A Phase Ib Trial of Oncoquest-CLL Vaccine for Treatment-Naive Patients with Chronic Lymphocytic Leukemia
Ma, S. (PD/PI)
10/30/13 → 10/30/25
Project: Research project
-
Prot#NU 10H06: Correlative Studies In Conjunction with A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination In Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
Ma, S. (PD/PI) & Goolsby, C. L. (Co-Investigator)
National Comprehensive Cancer Network, Novartis Pharmaceuticals Corporation
5/20/11 → 12/1/25
Project: Research project
-
Prot #COMB157BUS25T//NU 10H06: A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
Ma, S. (PD/PI), Frankfurt, O. (Co-PD/PI), Gordon, L. I. (Co-PD/PI) & Winter, J. N. (Co-PD/PI)
Novartis Pharmaceuticals Corporation
4/21/11 → 12/31/25
Project: Research project
-
Finished
Prot #U2-VEN-109: Phase I/II Study of Venetoclax in Combination with Ublituximab and Umbralisib (TGR-1202) in Patients with Relapsed or Refractory CLL/SLL
Ma, S. (PD/PI)
4/12/19 → 4/12/24
Project: Research project
-
Prot #INCB50465-204: A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)
Ma, S. (PD/PI)
Covance Inc., Incyte Corporation
1/24/18 → 1/24/21
Project: Research project
-
Prot #MEDI4736-NHL-001: A Phase 1/2, Open Label, Multicenter Study To Assess The Safety And Tolerability Of Durvalumab (Anti-PD-L1 Antibody) As Monotherapy And In Combination Therapy In Subjects With Lymphoma Or Chronic Lymphocytic Leukemia
Ma, S. (PD/PI)
ICON plc, Celgene International II Sàrl
6/30/17 → 6/30/20
Project: Research project
-
Prot #M15-330: A Phase 1b/2 Study of Duvelisib and Venetoclax in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3
Ma, S. (PD/PI)
3/3/16 → 3/3/19
Project: Research project
-
Prot #M14-032: A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia Subjects with Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
Ma, S. (PD/PI)
INC Research, LLC, AbbVie Inc.
12/18/14 → 12/31/22
Project: Research project